Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

11K characters. Original on sec.gov · Markdown

Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

A. (1) List of Financial Statements.

The following Consolidated Financial Statements are filed as part of this Annual Report on Form 10-K:

Consolidated Statements of Earnings and Comprehensive Income for the Years Ended June 30, 2014, 2013

and 2012

Consolidated Balance Sheets as of June 30, 2014 and 2013

Consolidated Statements of Shareholders’ Equity for the Years Ended June 30, 2014, 2013 and 2012

Consolidated Statements of Cash Flows for the Years Ended June 30, 2014, 2013 and 2012

Notes to Consolidated Financial Statements for the Years Ended June 30, 2014, 2013 and 2012

Report of Independent Registered Public Accounting Firm

A. (2) Financial Statement Schedules.

All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the Consolidated Financial Statements or Notes thereto.

A. (3) Exhibits.

See “Exhibit Index” immediately following signature page.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

TECHNE CORPORATION
Date: August 29, 2014/s/ Charles Kummeth
By: Charles Kummeth
Its: President

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

DateSignature and Title
August 29, 2014/s/ Robert V. Baumgartner
Robert V. Baumgartner
Chairman of the Board and Director
August 29, 2014/s/ Roger C. Lucas, Ph.D.
Dr. Roger C. Lucas
Vice Chairman and Director
August 29, 2014/s/ Howard V. O’Connell
Howard V. O’Connell, Director
August 29, 2014/s/ Randolph C. Steer, Ph.D., M.D.
Dr. Randolph C. Steer, Director
August 29, 2014/s/ Charles A. Dinarello, M.D.
Dr. Charles A. Dinarello, Director
August 29, 2014/s/ Karen A. Holbrook, Ph.D.
Dr. Karen A. Holbrook, Director
August 29, 2014/s/ John L. Higgins
John L. Higgins, Director
August 29, 2014/s/ Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Director
August 29, 2014/s/ Harold J. Wiens
Harold J. Wiens, Director
August 29, 2014/s/ Charles Kummeth
Charles Kummeth, Chief Executive Officer
(principal executive officer)
August 29, 2014/s/ James Hippel
James Hippel, Chief Financial Officer
(principal financial officer and principal accounting officer)
Table of Contents

EXHIBIT INDEX

for Form 10-K for the 2014 Fiscal Year

Exhibit NumberDescription
3.1Restated Bylaws of Company, as amended to date – incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated October 25, 2012.*
3.2Restated Articles of Incorporation of the Company, as amended to date – incorporated by reference to Exhibit 3.2 of the Company’s Form 8-K, dated October 25, 2012.*
10.1**Company’s Profit Sharing Plan – incorporated by reference to Exhibit 10.6 of the Company’s Form 10, dated October 27, 1988.*
10.2**Company’s Stock Bonus Plan – incorporated by reference to Exhibit 10.7 of the Company’s Form 10, dated October 27, 1988.*
10.3**1997 Incentive Stock Option Plan – incorporated by reference to Exhibit 10.24 of the Company’s Form 10-K for the year ended June 30, 1997.*
10.4**Form of Stock Option Agreement for 1997 Incentive Stock Option Plan – incorporated by reference to Exhibit 10.25 of the Company’s Form 10-K for the year ended June 30, 1997.*
10.5**1998 Nonqualified Stock Option Plan – incorporated by reference to Exhibit 10.1 of the Company’s Form 10-Q for the quarter ended September 30, 1998.*
10.6**Form of Stock Option Agreement for 1998 Nonqualified Stock Option Plan – incorporated by reference to Exhibit 10.2 of the Company’s Form 10-Q for the quarter ended September 30, 1998.*
10.7Amended and Restated Investors Rights Agreement dated June 13, 2006 among ChemoCentryx, Inc and the Company and certain investors – incorporated by reference to Exhibit 10.31 of the Company’s 10-K for the year ended June 30, 2006.*
10.8**Description of Management Incentive Bonus Under the Techne Corporation 2010 Equity Incentive Plan – incorporated by reference to Exhibit 10.13 of the Company’s 10-K for the year ended June 30, 2013.*
10.9**2010 Equity Incentive Plan – incorporated by reference to Exhibit 10.1 of the Company’s 8-K dated October 28, 2010.*
10.10**Form of Nonqualified Stock Option Agreement for the 2010 Equity Incentive Plan – incorporated by reference to Exhibit 10.2 of the Company’s 8-K dated October 28, 2010.*
10.11**Form of Incentive Stock Option Agreement for the 2010 Equity Incentive Plan – incorporated by reference to Exhibit 10.3 of the Company’s 8-K dated October 28, 2010.*
10.12**Amended and Restated Employment Agreement, dated July 1, 2011, with Marcel Veronneau – incorporated by reference to Exhibit 10.19 of the Company’s 10-K for the year ended June 30, 2011.*
Table of Contents
Exhibit NumberDescription
10.13**Employment Agreement by and between the Company and Charles Kummeth – incorporated by reference to Exhibit 10.1 of the Company’s 8-K dated March 16, 2013.*
10.14**Form of Restricted Stock Agreement for the 2010 Equity Incentive Plan – incorporated by reference to Exhibit 10.1 of the Company’s 10-Q for the quarter ended March 31, 2013.*
10.15**Amendment No. 2 to Amended and Restated Employment Agreement, dated April 12, 2013, with Gregory J. Melsen – incorporated by reference to Exhibit 10.23 of the Company’s 10-K for the year ended June 30, 2013.*
10.16Share Purchase Agreement by and among Research and Diagnostic Systems, Inc., Bionostics Holdings Limited, Bionostics, Inc., the shareholders of Bionostics Holdings Limited, and Harwood Capital, LLP as Sellers’ Representative, dated June 17, 2013 – incorporated by reference to Exhibit 2.1 of the Company’s 8-K dated June 17, 2013.*
10.17**Description of Non-employee Director Compensation Plan – incorporated by reference to Exhibit 10.25 of the Company’s 10-K for the year ended June 30, 2013.*
10.18**Employment Agreement by and between the Company and Kevin Reagan, dated January 24, 2012 – incorporated by reference to Exhibit 10.26 of the Company’s 10-K for the year ended June 30, 2013.*.
10.19**Employment Agreement by and between the Company and Dr. J. Fernando Bazan, dated August 1, 2013 – incorporated by reference to Exhibit 10.27 of the Company’s 10-K for the year ended June 30, 2013.*
10.20**Compensation Arrangement for the Executive Officers for Fiscal Year 2014 – incorporated by reference to Exhibit 10.28 of the Company’s 10-K for the year ended June 30, 2013.*
10.21**Employment Agreement by and between the Company and Mr. James T. Hippel, dated February 5, 2014 – incorporated by reference to Exhibit 10.1 of the Company’s 8-K dated February 5, 2014.*
10.22Agreement of Investment and Merger between the Company, Research and Diagnostics Systems, Inc., Cayenne Merger Sub, Inc., CyVek, Inc. and Citron Capital Limited dated April 1, 2014.
10.23Agreement and Plan of Merger by and among Techne Corporation, McLaren Merger Sub, Inc., ProteinSimple and Fortis Advisors LLC, as the Securityholders’ Representative, dated June 16, 2014 – incorporated by reference to Exhibit 2.1 of the Company’s 8-K dated June 16, 2014.*
10.24Unit Purchase Agreement by and among Techne Corporation, Novus Holdings, LLC, the Members of Novus Holdings, LLC, and the Members’ Representative dated July 2, 2014.
10.25**Employment Agreement by and between the Company and Mr. David Eansor, dated July 2, 2014.
10.26Credit Agreement by and among Techne Corporation, the Guarantors party thereto, the Lenders party thereto, and BMO Harris Bank N.A., as Administrative Agent, dated July 28, 2014 – incorporated by reference to Exhibit 10.1 of the Company’s 8-K dated July 28, 2014.*
10.27Form of Indemnification Agreement entered into with each director and executive officers of the Company.
21Subsidiaries of the Company.
Table of Contents
Exhibit NumberDescription
23Consent of KPMG LLP, Independent Registered Public Accounting Firm.
31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101The following financial statements from the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Statements of Earnings and Comprehensive Income, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Shareholders’ Equity, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.
*Incorporated by reference; SEC File No. 000-17272
**Management contract or compensatory plan or arrangement

Previous: Item 14. PRINCIPAL ACCOUNTING FEES AND SERVICES